Dave Asprey Listeners Discount

As a thank you to loyal podcast listeners, we are offering a limited-time discount of $50 off the Galleri test for the first 500 tests. 

Enter the Galleri Key 50DAVE2024 to receive $50 off.

Offer ends July 5, 2024 at 11:59 pm PST. 

See Important Safety Information

See Terms and Conditions

Rx Only. Test requests will be reviewed by an independent telemedicine provider.

The Human Upgrade with Dave Asprey

What is the Galleri test?

Galleri is a multi-cancer early detection (MCED) test that looks for a signal shared by more than 50 types of cancer. It's a screening test, which means that while it does not diagnose cancer, it can improve your chance of finding it early.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests.

Galleri identifies DNA in the bloodstream shed by cancer cells, and does not predict future genetic risk for cancer.


Who is Galleri for?

The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.

Age is the biggest risk factor for cancer. In fact, adults over age 50 are 13 times more likely to have cancer compared to people under the age of 50.1 Cancer risk increases for everyone as they age regardless of family history—only 5% to 10% of cancers are inherited.1,2

  • The Galleri test is available by prescription only.

  • Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of ​“No Cancer Signal Detected” does not rule out cancer. A test result of ​“Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

$50 discount offer ends July 5th, 2024, at 11:59 pm PST or when the first 500 telemedicine orders have been placed using the Galleri Key "50DAVE2024".

This offer is only available for Galleri tests requested online at Galleri.com through an independent telemedicine provider. You must be 50 years or older to take advantage of the offer. Eligibility will be assessed at the time of your test request. The discount only applies to full-priced, self-pay tests priced at $949. Galleri is not covered by most health insurance plans.

Limited time offer valid only for Galleri test orders placed April 1, 2024, 12:00 am PST through July 5, 2024, 11:59 pm PST. Valid only for the first 500 Galleri test orders requested online and approved by GRAIL’s contracted independent telemedicine healthcare provider using the Galleri Key "50DAVE2024". Offer does not confirm your eligibility for the Galleri test. Valid only for one-time use on domestic U.S. Galleri test orders only. Offer valid only for discount off of list price Galleri test orders ($949) and cannot be combined or used with any other discount, promotion, special pricing, or payment plan. Cannot be used to request a credit on a test order placed prior to the offer period. Cannot be posted online or on any other unapproved publicly available forum. GRAIL reserves the right to change terms and conditions, substitute offer of equal or greater value, and end offer at any time without notice. You must create an account to redeem this offer and enter the code at the “Introduction” stage, where prompted.

  1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database Incidence - SEER Research Limited-Field Data, 21 Registries, Nov 2020 Sub (2000-2018) - Linked To County Attributes -Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission. Risk Factor Data on file: American Cancer Society Cancer Prevention Studies II/III.

  2. NIH/National Cancer Institute. Genetic testing for inherited cancer susceptibility syndromes. Accessed 3Mar2023. https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet.